| pubmed-article:9879698 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9879698 | lifeskim:mentions | umls-concept:C0026973 | lld:lifeskim |
| pubmed-article:9879698 | lifeskim:mentions | umls-concept:C0028778 | lld:lifeskim |
| pubmed-article:9879698 | lifeskim:mentions | umls-concept:C0027788 | lld:lifeskim |
| pubmed-article:9879698 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:9879698 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:9879698 | lifeskim:mentions | umls-concept:C0449774 | lld:lifeskim |
| pubmed-article:9879698 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9879698 | pubmed:dateCreated | 1999-3-23 | lld:pubmed |
| pubmed-article:9879698 | pubmed:abstractText | We studied the pattern of human antiganglioside antibody reactivities causing an acute conduction block in rat myelinated nerve fibers, using an in vitro preparation of the sciatic-tibial nerve. With the aid of complements, IgM antibodies reacting with the terminal disaccharide of galactose (beta1-3)N-acetylgalactosamine produced the block. These findings may help us to understand the mechanism in which the conduction block occurs in neuropathies associated with antiganglioside antibodies. | lld:pubmed |
| pubmed-article:9879698 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9879698 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9879698 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9879698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9879698 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9879698 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:9879698 | pubmed:issn | 0022-510X | lld:pubmed |
| pubmed-article:9879698 | pubmed:author | pubmed-author:TamakiMM | lld:pubmed |
| pubmed-article:9879698 | pubmed:author | pubmed-author:KudoNN | lld:pubmed |
| pubmed-article:9879698 | pubmed:author | pubmed-author:KusunokiSS | lld:pubmed |
| pubmed-article:9879698 | pubmed:author | pubmed-author:ArasakiKK | lld:pubmed |
| pubmed-article:9879698 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9879698 | pubmed:day | 11 | lld:pubmed |
| pubmed-article:9879698 | pubmed:volume | 161 | lld:pubmed |
| pubmed-article:9879698 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9879698 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9879698 | pubmed:pagination | 163-8 | lld:pubmed |
| pubmed-article:9879698 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:meshHeading | pubmed-meshheading:9879698-... | lld:pubmed |
| pubmed-article:9879698 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9879698 | pubmed:articleTitle | The pattern of antiganglioside antibody reactivities producing myelinated nerve conduction block in vitro. | lld:pubmed |
| pubmed-article:9879698 | pubmed:affiliation | Department of Neurology, NTT Kanto Teishin Hospital, Tokyo, Japan. arasaki@kth.ntt.co.jp | lld:pubmed |
| pubmed-article:9879698 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9879698 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9879698 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:9879698 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9879698 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9879698 | lld:pubmed |
